Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.2%

61 terminated/withdrawn out of 1442 trials

Success Rate

92.6%

+6.0% vs industry average

Late-Stage Pipeline

16%

236 trials in Phase 3/4

Results Transparency

2%

15 of 767 completed trials have results

Key Signals

124 recruiting15 with results31 terminated30 withdrawn

Enrollment Performance

Analytics

N/A
637(60.2%)
Phase 4
197(18.6%)
Phase 2
143(13.5%)
Phase 1
42(4.0%)
Phase 3
39(3.7%)
1058Total
N/A(637)
Phase 4(197)
Phase 2(143)
Phase 1(42)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1442)

Showing 20 of 1442 trials
NCT06976580Not ApplicableCompleted

Effect of Skin Stretching on Pain Reduction During Local Anesthetic Injections: A Randomized Clinical Study

Role: lead

NCT07845877Not ApplicableNot Yet Recruiting

An Intervention to Reduce Sedentary Behavior and Promote Physical Activity in Colorectal Cancer Chemotherapy

Role: lead

NCT07843901Phase 2Not Yet Recruiting

Lenvatinib in Patients With Advanced Parathyroid Carcinoma

Role: lead

NCT07804407Recruiting

Prospective Evaluation of AI Generated History of Present Illness Drafts in the Emergency Department

Role: lead

NCT07824414Recruiting

Prognostic Value of Pulse Oximetry Differences

Role: lead

NCT07817901Phase 1Not Yet Recruiting

Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma

Role: lead

NCT07814144Phase 4Active Not Recruiting

Venous Closure System After AF Ablation

Role: lead

NCT07813273Not Yet Recruiting

Coronary Access After Evolut FX Plus TAVI: Impact of Commissural Alignment and the Large-Cell Frame Design: ACCESS-FX+ Registry

Role: lead

NCT07804381Phase 2Not Yet Recruiting

Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease

Role: lead

NCT07640932Phase 2Not Yet Recruiting

Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer

Role: lead

NCT07804394Not ApplicableNot Yet Recruiting

Procedural Endpoint in Left Bundle Branch Area Pacing: Conduction System Capture Versus LV Septal Capture

Role: lead

NCT04250116Phase 4Completed

Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

Role: lead

NCT07798921Phase 1Not Yet Recruiting

JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure

Role: lead

NCT07788222Phase 2Not Yet Recruiting

Sacituzumab Govitecan and Q901 in Advanced TNBC

Role: lead

NCT04910347Phase 2Active Not Recruiting

Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Role: lead

NCT07760129Not Yet Recruiting

Erector Spinae Oxygen Saturation and AKI After OPCAB

Role: lead

NCT05782465Active Not Recruiting

Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study)

Role: collaborator

NCT07751796Not ApplicableNot Yet Recruiting

OptiCross HD IVUS for Assessing Invasion Depth in Upper Tract Urothelial Carcinoma

Role: lead

NCT07751809Completed

AI-ECG for Predicting CMR-Defined Myocardial Injury in Acute Myocardial Infarction

Role: lead

NCT02038127Recruiting

Gangwon PCI Prospective Registry

Role: lead